Indian Pharmaceutical Market Outlook Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment provides in-depth analysis of the trends, issues and challenges facing the Indian pharmaceutical market. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The Indian pharmaceutical industry grew from $0.8 billion in 1980 to $21.73 billion in 2010 and is expected to grow further as Multinational Companies (MNCs) enter the market. Although pharmaceutical giants such as GlaxoSmithKline (GSK) have been present in the market for years, the rising income of the middle-class population, changing patent laws, low-cost skilled labor and low-priced infrastructure in India have attracted other MNCs. With the current scenario, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 12% during the 20112015 period. Branded generics are expected to become more prevalent in India as many global players are planning to launch them after their patents expire.

1. Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded
access to healthcare attracting Big Pharma investment
Indian Pharmaceutical Market Outlook Enhanced purchasing power, rural market penetration and expanded
access to healthcare attracting Big Pharma investment
Summary
GBI Researchs new report Indian Pharmaceutical Market Outlook Enhanced purchasing power, rural market
penetration and expanded access to healthcare attracting Big Pharma investment provides in-depth analysis of
the trends, issues and challenges facing the Indian pharmaceutical market. It is built using data and
information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI
Researchs team of industry experts. The Indian pharmaceutical industry grew from $0.8 billion in 1980 to
$21.73 billion in 2010 and is expected to grow further as Multinational Companies (MNCs) enter the market.
Although pharmaceutical giants such as GlaxoSmithKline (GSK) have been present in the market for years,
the rising income of the middle-class population, changing patent laws, low-cost skilled labor and low-priced
infrastructure in India have attracted other MNCs. With the current scenario, the market is expected to grow at
a Compound Annual Growth Rate (CAGR) of 12% during the 20112015 period. Branded generics are
expected to become more prevalent in India as many global players are planning to launch them after their
patents expire.
The once highly fragmented Indian pharmaceutical industry is undergoing strategic consolidations with the
aim of emerging as a highly organized sector. With the inflow of MNCs R&D operations the industry will
continue to experience a trend of M&A. Deals and acquisitions are set to continue due to low-cost
infrastructure and labor as patent expiries and the thin pipelines of major companies will cause revenues to
fall.
The Indian government has implemented various initiatives to increase insurance coverage and reduce
healthcare costs, such as the National Rural Health Mission and Jan Aushadhi. A revised pricing policy was
also proposed in 2011, which will increase government control to over 60% of drugs.
Rising income levels, changing disease patterns, increasing reach of healthcare, reduced out-of-pocket
expenditure and growth of new products such as generics and biosimilars are expected to drive growth in the
future.
Scope
Macroeconomic environment of the pharmaceutical industry in India, covering demographic analysis,
drivers, and barriers Important industry characteristics, looking at healthcare policies, regulations, distribution,
pricing, taxation, spending, insurance and reimbursement Market analysis of segments such as prescription
medicines, biotechnology, over-the-counter medicines and Contract Research and Manufacturing Services
(CRAMS) Annualized market data from 2005 to 2010 for important therapeutic segments Competitive
profiling of five major domestic and international companies operating in the Indian pharmaceutical market
Analysis of licensing, partnership and M&A deals that took place between 2007 and 2011
Reasons to buy
Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting B

2. Develop market-entry and market-expansion strategies by identifying the leading segments poised for strong
growth Device a more tailored country strategy through understanding key drivers of and barriers to the
pharmaceutical market Develop key strategic initiatives by understanding leading companies key focus areas
Accelerate and strengthen your market position by identifying key companies for M&A and strategic
partnerships
table Of Contents
1 Table Of Contents
1 Table Of Contents 5
1.1 List Of Tables 8
1.2 List Of Figures 9
2 Indian Pharmaceutical Market Outlook Introduction 10
3 Indian Pharmaceutical Market Outlook Overview 11
3.1 Global Pharmaceutical Industry Landscape 11
3.2 Macro View Of The Indian Pharmaceutical Sector 12
3.3 Demographic Analysis 13
3.3.1 Population Size, Growth, And Structure 13
3.3.2 Crude Death Rate 15
3.3.3 Infant Mortality Rate 16
3.3.4 Life Expectancy At Birth 17
3.4 Driver And Barriers 19
3.4.1 Drivers 19
3.4.2 Barriers 21
3.5 Swot Analysis Of Indian Pharmaceutical Industry 22
4 Indian Pharmaceutical Market Outlook Industry Characteristics 23
4.1 Healthcare Policy 23
4.1.1 National Health Policy 2002 23
4.1.2 National Rural Health Mission 23
4.1.3 National Urban Health Mission 24
4.2 Intellectual Property Rights In India 25
4.2.1 Effect Of Patent Laws On Pharmaceutical Production In India 26
4.2.2 Key Impact Of The New Patent Laws On India 27
4.2.3 Patent Act 2005 First Step Towards Improving Ip Protection 27
4.2.4 Ipr Enforcement Rules 2007 27
4.2.5 Trademarks Bill 2007 27
Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting B

3. 4.2.6 Drugs And Cosmetics Act (amendment) 2008 27
4.3 Drug Distribution Structure 28
4.4 National Pharmaceuticals Pricing Policy 29
4.4.1 Objectives Of The Present Policy 29
4.4.2 Key Principles Of National Pharmaceuticals Pricing Policy, 2011 29
4.4.3 Principles For Drug Price Control And Determination In National Pharmaceutical Pricing Policy 2011
30
4.4.4 Other Aspects Of The Policy 30
4.4.5 Impact Analysis Of The Policy 31
4.5 Goods And Services Tax 31
4.5.1 An Introduction To Goods And Services Tax 31
4.5.2 Dual Goods And Services Tax In India 31
4.5.3 Impact On The Pharmaceutical Industry 32
4.6 Direct Tax Code 33
4.6.1 Tax Structure 33
4.6.2 Incentives Available To The Pharmaceutical Sector 33
4.6.3 Road Ahead 33
4.7 Healthcare Spending In India 34
4.8 Insurance And Reimbursement 35
4.8.1 Private Health Insurance 35
4.8.2 Health Insurance Companies Landscape 36
5 Indian Pharmaceutical Market Outlook Market Analysis 37
5.1 Market Overview 37
5.1.1 Contract Research And Manufacturing Services 37
5.1.2 Biotech 38
5.1.3 Over-the-counter Drugs 42
5.1.4 Prescription Drugs 42
5.1.5 Herbal Medicines 43
5.2 Market Segmentation 44
6 Indian Pharmaceutical Market Outlook Market Analysis By Therapeutic Categories 46
6.1 Market Share Of Leading Therapeutic Segment 46
6.2 Anti-infectives 47
6.2.1 Market Size 47
6.2.2 Key Brands And Players 48
6.2.3 Recent Developments 48
6.2.4 Outlook 48
6.3 Cardiovascular System 49
6.3.1 Market Size 49
6.3.2 Recent Developments 50
Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting B

4. 6.3.3 Outlook 50
6.4 Gastrointestinal 51
6.4.1 Market Size 51
6.4.2 Recent Developments 52
6.4.3 Outlook 52
6.5 Diabetes 53
6.5.1 Market Size 53
6.5.2 Recent Developments 54
6.5.3 Outlook 54
6.6 Central Nervous System 55
6.6.1 Market Size 55
6.6.2 Recent Developments 56
6.6.3 Outlook 56
6.7 Respiratory 57
6.7.1 Market Size 57
6.7.2 Recent Developments 58
6.7.3 Outlook 58
6.8 Dermatology 59
6.8.1 Market Size 59
6.8.2 Recent Developments 60
6.8.3 Outlook 60
6.9 Oncology 61
6.9.1 Market Size 61
6.9.2 Recent Developments 62
6.9.3 Outlook 62
7 Indian Pharmaceutical Market Outlook Key Trends 63
7.1 Rapid Consolidation And Rise Of Multinational Corporations In The Indian Pharmaceutical Industry 63
7.1.1 M&a Deals 63
7.1.2 Licensing Deals 65
7.1.3 Partnership Deals 66
7.2 Patent Litigations Favoring Generics 67
7.2.1 Indian Patent Office Revokes Patent For Pfizers Cancer Drug Sutent (sunitinib) 67
7.2.2 Indian Appeals Body Dismisses Bayers Plea For Stay On Natco's Generic Nexavar (sorafenib) 67
7.2.3 Delhi High Court Rules In Favor Of Cipla In Roche's Tarceva (erlotinib) Patent Lawsuit 67
7.2.4 Indian Supreme Court Asks Novartis To Scale Down Price Of Cancer Drug Glivec (imatinib) 67
7.3 Increasing Importance Of Rural Marketing In India 68
7.3.1 Case Study - Novartis Arogya Parivar Case Study 68
7.4 Product Localization And India-specific Pricing 70
7.4.1 Case Study - Glaxosmithkline, Localized Business Model 70
7.5 Sales Strategies 71
7.5.1 Case Study - Mankind, Sales Excellence 71
Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting B

5. 7.6 Patented Products Introduced In Niche Segments 72
7.6.1 Case Study - Mercks Successful Strategy For Patented Products 72
7.7 Actions Taken By Indian Government Against Counterfeit Drugs 73
8 Indian Pharmaceutical Market Outlook Competitive Landscape 74
8.1 Key Foreign Companies 74
8.1.1 Sanofi 74
8.1.2 Roche 74
8.1.3 Astrazeneca 75
8.1.4 Glaxosmithkline 75
8.1.5 Abbott Laboratories 75
8.2 Key Domestic Companies 76
8.2.1 Dr. Reddys Laboratories 76
8.2.2 Lupin 78
8.2.3 Cipla Limited 80
8.2.4 Ranbaxy Laboratories Limited 81
8.2.5 Biocon 83
9 Indian Pharmaceutical Market Outlook The Way Forward 85
9.1 Outlook For The Indian Pharmaceutical Industry 85
9.2 Risks 86
9.2.1 Currency Fluctuation And Financial Problems Will Make It Difficult To Sustain Growth 86
9.2.2 Regulatory Hurdles 86
9.2.3 Financial Disparity 86
9.2.4 Intellectual Property Concerns 86
9.3 Recommendations 87
9.3.1 Improved Links Between Industry And Academia 87
9.3.2 Focus On R&d Initiatives And Skilled Manpower 87
9.3.3 Support For Clinical Trials Sector 87
9.3.4 Quality Drugs To Be Made Affordable And Accessible 87
9.4 Opportunities Ahead 88
9.5 Strategies For Future Success 88
9.5.1 Increasing Importance Of Biosimilars 88
9.5.2 Rural Markets 89
10 Indian Pharmaceutical Market Outlook Appendix 90
10.1 Market Definitions 90
10.2 Abbreviations 90
10.3 Bibliography 92
10.4 Research Methodology 93
Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting B

6. 10.4.1 Coverage 93
10.4.2 Secondary Research 93
10.4.3 Primary Research 93
10.4.4 Expert Panel Validation 94
10.5 Contact Us 94
10.6 Disclaimer 94
About Us:
Transparency Market Research is a market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of
Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
ResearchMoz
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Blog: http://researchmoz.blogspot.com/
Website: http://www.researchmoz.us/
Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting B